Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Authors: Aguirre, Clara; Meca-Lallana, Virginia; Sanchez, Pedro; Vivancos, Jose
Abstract
Alemtuzumab is an anti-CD52 monoclonal antibody approved for the treatment of multiple sclerosis (MS). It produces rapid depletion of T and B lymphocytes, which could predispose to opportunistic infections. We report one patient with MS who develops cytomegalovirus (CMV) primary infection after a third cycle of alemtuzumab, with spontaneous recovery associated with rapid lymphocyte reconstitution.
Immune status following alemtuzumab treatment in human CD52 transgenic mice
JOURNAL OF NEUROIMMUNOLOGY
Authors: Turner, Michael J.; LaMorte, Michael J.; Chretien, Nathalie; Havari, Evis; Roberts, Bruce L.; Kaplan, Johanne M.; Siders, William M.
Abstract
Alemtuzumab is a monoclonal antibody against the CD52 antigen present at high levels on the surface of lymphocytes. While treatment of multiple sclerosis patients with alemtuzumab results in marked depletion of lymphocytes from the circulation, it has not been associated with a high incidence of serious infections. In a human CD52 transgenic mouse, alemtuzumab treatment showed minimal impact on the number and function of innate immune cells. A transient decrease in primary adaptive immune responses was observed post-alemtuzumab but there was little effect on memory responses. These results potentially help explain the level of immunocompetence observed in alemtuzumab-treated MS patients. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
COA
Publication 
Loading ......
